ASSOCIATION BETWEEN CYP2C9 PROMOTER REGION VARIANTS AND WARFARIN DOSE REQUIREMENTS IN AFRICAN AMERICANS.

被引：0
|
作者：
Cavallari, L. [1 ]
Drozda, K. [1 ]
Perera, M. [2 ]
Patel, S. [1 ]
Shapiro, N. [1 ]
Nutescu, E. [1 ]
Stamos, T. [1 ]
机构：
[1] Univ Illinois, Chicago, IL USA
[2] Univ Chicago, Chicago, IL 60637 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2011年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S77 / S78
页数：2
相关论文
共 50 条
  • [21] First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele
    O'Brien, Travis J.
    Kidd, Robert S.
    Richard, Craig A. H.
    Ha, Ngoc-Han
    Witcher, Preston
    Tran, Linda V.
    Barbour, April
    Tuck, Matthew
    McIntosh, Samantha D.
    Douglas, Jacqueline N.
    Harralson, Arthur F.
    CLINICA CHIMICA ACTA, 2013, 424 : 73 - 75
  • [22] Warfarin dose requirement and CYP2C9 polymorphisms -: Reply
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    LANCET, 1999, 353 (9168): : 1972 - 1973
  • [23] Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose
    Zhao, F
    Loke, C
    Rankin, SC
    Guo, JY
    Lee, HS
    Wu, TS
    Tan, T
    Liu, TC
    Lu, WL
    Lim, YT
    Zhang, Q
    Goh, BC
    Lee, SC
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (03) : 210 - 219
  • [24] Pharmacogenetic Impact of VKORC1 and CYP2C9 Allelic Variants on Warfarin Dose Requirements in a Hispanic Population Isolate
    Palacio, Lina
    Falla, Diana
    Tobon, Ignacio
    Mejia, Fernando
    Lewis, John E.
    Martinez, Ariel F.
    Arcos-Burgos, Mauricio
    Camargo, Mauricio
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2010, 16 (01) : 83 - 90
  • [25] Frequency analysis and correlation of newer variants alleles of CYP2C9 and warfarin dose.
    Kidd, R.
    Johnson, M.
    Richard, C.
    Adkins, J.
    Harralson, A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1085 - 1085
  • [26] Mechanistic insights into the effect of CYP2C9*2 and CYP2C9*3 variants on the 7-hydroxylation of warfarin
    Pavani, Addepalli
    Naushad, Shaik Mohammad
    Stanley, Balraj Alex
    Kamakshi, Renganathan Gnanambal
    Abinaya, Krishnan
    Rao, Malempati Amaresh
    Uma, Addepally
    Kutala, Vijay Kumar
    PHARMACOGENOMICS, 2015, 16 (04) : 393 - 400
  • [27] Association of CYP2C9 Genetic Variants with Vitiligo
    Alzolibani, Abdullateef A.
    Al Robaee, Ahmad
    Al-Shobaili, Hani
    Al-Saif, Fahad
    Al-Mekhadab, Eman
    Settin, Ahmed A.
    ANNALS OF DERMATOLOGY, 2014, 26 (03) : 343 - 348
  • [28] Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans
    Limdi, Nita A.
    KArnett, Donna
    Goldstein, Joyce A.
    Beasley, T. Mark
    McGwin, Gerald
    Adler, Brian K.
    Acton, Ronald T.
    PHARMACOGENOMICS, 2008, 9 (05) : 511 - 526
  • [29] Analysis of CYP2C9 polymorphisms (*2 and*3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR
    Yasmeen, Faiza
    Ghafoor, Muhammad Bilal
    Khalid, Abdul Wadood
    Latif, Waqas
    Mohsin, Shahida
    Khaliq, Shagufta
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 40 (02) : 218 - 224
  • [30] Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR
    Faiza Yasmeen
    Muhammad Bilal Ghafoor
    Abdul Wadood Khalid
    Waqas Latif
    Shahida Mohsin
    Shagufta Khaliq
    Journal of Thrombosis and Thrombolysis, 2015, 40 : 218 - 224
12345